Janice Kang. Asymptomatic 5 yo F w/ family history of MEN 2A  Mother, brother w/ prophylactic thyroidectomy at age 8. Maternal grandfather died of complications.

Slides:



Advertisements
Similar presentations
Thyroid Cancer -- Papillary
Advertisements

Case 20 Thomas J. Giordano, M.D., Ph.D.. History A 54-year old man with a past medical history of goiter for approximately 4 years was followed by ultrasound.
Copyright © 2004 Pearson Education, Inc., publishing as Benjamin Cummings Endocrine Surgery.
Thyroid Cancer May 10, 2006.
Management of Secondary and Tertiary Hyperparathyroidism - Joint Hospital Grandround Henry Joeng Department of Surgery United Christian Hospital,
Dr Annie NK Chiu United Christian Hospital Joint Hospital Surgical Grand Round 20 th Apr 2013.
Management of Papillary Ca Thyroid
Thyroid nodule History History Physical examination Physical examination –Euthyroid –Hypothyroid –Hyperthyroid Labs Labs –TSH –(antibodies)
RET Multiple Endocrine Neoplasia Type 2 (MEN2) Brooke Martin 3/20/08.
Evolution of Parathyroid Surgery Using Sestamibi Imaging Guidance David R. Byrd, MD Department of Surgery University of Washington.
Update in the Management of Thyroid Neoplasms University of Washington
Personalized Medicine in the Era of Genomics Wylie Burke MD PhD Department of Medical History and Ethics Center for Genomics and Healthcare Equality University.
12 th G. Rainey Williams Surgical Symposium What Operation for Thyroid Cancer? Ronald Squires, MD FACS Associate Professor of Surgery Sections of General.
Joint Hospital Surgical Grand Round PYNEH, 18th April 2015
Management of GIST Dr Kwan Ming Wa Tuen Mun Hospital.
Emad Raddaoui, MD, FCAP, FASC Associate Professor; Consultant Histopathology & Cytopathology.
Management of differentiated thyroid cancer Dr. Leung Tak Lun Canice North District Hospital.
RET Proto-Oncogene of Multiple Endocrine Neoplasia type 2(MEN2)
THYROID CANCER.
Focus on endocrine neoplasia July 9, 2010 Rome Furio Pacini Dipartimento di Medicina Interna e Scienze Endocrino-Metaboliche Università di Siena Differentiated.
Thyroid Cancer Dr. Awad Alqahtani Md,MSc.FRCSC(G.Surgery)FRCSC(Surgical Oncology) Laparoscopic and Bariatric Surgery.
Role of Neck Dissection for Differentiated Thyroid CA Joint Hospital Surgical Grand Round NDH Dr. Alex TSANG.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Vic V. Vernenkar, D.O. St. Barnabas Hospital Department of Surgery
Thyroid nodules and neoplasms EMAD RADDAOUI, MD, FCAP, FASC ASSOCIATE PROFESSOR; CONSULTANT HISTOPATHOLOGY & CYTOPATHOLOGY.
Comparative quantitative evaluation of the XIAP, survivin & Ki67 transcript levels in urine & tissue samples of bladder cancer patients.
Thyroid Cancer 2005 Nancy Fuller, M.D. University of Wisconsin-Madison.
ד"ר חגי מזא"ה כירורגיה אנדוקרינית מבואות כירורגיה שנה ד'
Approach to a thyroid nodule
Lymphadenectomy in Epithelial Ovarian Cancer
Thyroid Gland. - The first endocrine gland to develop. - Endodermal origin. - Originates from the ventral embryologic digestive tract. - midline diverticulum.
MULTIPLE ENDOCRINE NEOPLASIA
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.
Li, Henry Winston Li, Kingbherly Lichauco, Rafael Lim, Imee Loren Lim, Jason Morven Lim, John Harold.
VCU DEATH AND COMPLICATIONS CONFERENCE. Brief Overview of Case  Diagnosis:  Papillary thyroid cancer  Primary hyperparathyroidism  Procedure:  Total.
Thyroid Debate (Papillary Thyroid Cancer: Extent of Thyroidectomy) 30 Aug 2007 Surgery-OMMC JGGuerra, MD HCruz, MD.
Evaluation of Thyroid Nodules
Ishita Das
Primary hyperparathyroidism Surgical Approach Dr Mohammad AlShehri, Can. Board, FACS, D Med Edu. Professor of Surgery.
MRCS teaching 01 September 2015
MRI scan shows a 3- cm low- density suprarenal mass on the right side.
DEFINITION A case or a family with hormone-secreting or hormone- producing neoplasia in multiple tissue types It encompasses several types of etiology,
Question No.1 If you were the physician who initially saw the patient four years ago, what would you have done?
1. Clinical Impression? Differentials?. Thyroid Carcinoma commonly manifests as a painless, palpable, solitary thyroid nodule The patient's age at presentation.
MEDULLARY THYROID CANCER
Parathyroid gland Dr Heyam Awad FRCPath. Parathyroid gland.
MULTIPLE ENDOCRINE NEOPLASIA Dr. M. Sofi MD; FRCP (London); FRCPEdin; FRCSEdin.
Anaplastic thyroid cancer based on ATA guideline for Management of Patients with ATC. Thyroid. 2012;22: R3 이정록.
Pt ZJ 19yo M that presented to Seattle Children’s for evaluation of 3 lesions found on recent PET CT ◦ One large mass in the posterior mediastinum just.
Oncology 2016 Mark D. Browning, M.D. ’77 Thyroid & Gastric Cancer
Sonographic Extranodular and Intranodular Microcalcifications NIDHI AGRAWAL, MD VALERIE PECK, MD DIVISION OF ENDOCRINOLOGY, DIABETES AND METABOLISM NEW.
M ULTIPLE E NDOCRINE N EOPLASIA T YPE II: S URGICAL M ANAGEMENT Greta Riedesel, R3 12/9/2010.
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
Association of Family History with Cancer Recurrence and Survival in Patients with Gastric Cancer Journal of Clinical Oncology : R2 Hwang.
Virginia Sanders, MD PGY-1
MULTIPLE ENDOCRINE NEOPLASIA
The Elliott Breast Center * Baton Rouge, LA *
Multiple Endocrine Neoplasia
Conclusions We conclude that early thyroidectomy and central lymph node dissection is effective treatment for hereditary MTC at this interim time point.
Poster number MON 146 A Cough with an Adrenal Surprise First Case Report of Codon C609Y Presenting with Pheochromocytoma Inga Harbuz-Miller, MD1; Jennifer.
IN THE NAME OF GOD.
MULTIPLE ENDOCRINE NEOPLASIA
MEDULLARY THYROID CANCER
HAI PHONG UNIVERSITY OF MEDICINE AND PHARMACY
and multiple endocrine neoplasia type 2 (MEN2)
Cheng-Chiao Huang, MD, MSc
鄭學謙 吳哲維 王凌峰 江豐裕 高雄醫學大學附設醫院 耳鼻喉部
RET Receptor Ashley Bass.
Pituitary Gland Thyrotoxicosis Adrenal Gland Thyroid/Parathyroid
Presentation transcript:

Janice Kang

Asymptomatic 5 yo F w/ family history of MEN 2A  Mother, brother w/ prophylactic thyroidectomy at age 8. Maternal grandfather died of complications of cancer (unknown type).  Exon 11 RET mutation  Calcitonin 45 pg/mL  T4, T3, TSH, and PTH wnl  Urine metanephrines negative CASE PRESENTATION

Preoperative ultrasound

Operation  Total thyroidectomy and parathyroidectomy  Cystic lesion at left inferior pole sent for frozen section= hemorrhagic parathyroid tissue  2 superior parathyroid glands identified, bilateral RLNs identified  No node dissection

Familial Medullary Thyroid Cancer  Medullary thyroid cancer (~100% penetrance)  Pheochromocytoma  Hyperparathyroidism MEN 2A  Medullary thyroid cancer only (~100% penetrance)

MEN 2B  Medullary thyroid cancer (~100% penetrance)  Tumor develops at earlier age, more aggressive  Pheochromocytoma  Marfanoid habitus (w/o Marfan's syndrome), mucosal neuromas, intestinal ganglioneuromas

RET protein  Tyrosine kinase receptor that transduces growth and differentiation signals  Found in C cells of the thyroid gland, adrenal medulla, neuron, and other derivatives of neural crest cells.  Ligand binding  dimerization  signal transduction  Mutation = GAIN of function: ligand-independent dimerization and activation

When to operate with a known gene mutation? ATA risk stratification is dependent on RET genotype A Exons 13,14,15 mutations May delay operation >5 yo B Exon 10 mutation Operate < 5 yo C Exon 11 mutation Operate < 5 yo D Codon 918 mutation-MEN 2B Operate < 1 yo (youngest age at diagnosis = 9 mo)

Prognostic Factors of Disease-Free Survival after Thyroidectomy in 170 Young Patients with a RET Germline Mutation: A Multicenter Study of the Groupe Francais d’Etude des Tumeurs Endocrines  Retrospective analysis 170 pts <21 yo from hereditary MTC families  Total thyroidectomy [+ central or central+bilateral LND in 75% of pts]  Class, Tumor size, node status, preoperative basal CT, and age No patients with a preoperative basal CT <30 pg/mL had persistent or recurrent disease.

Tumor size >10 mm, node status (N1), A Exons 13,14,15 mutations DFS: 100% 3.7 yrs B Exon 10 mutation DFS: 95.5% 6.1 yrs C Exon 11 mutation DFS: 86.3% 7.7 yrs D Codon 918 mutation-MEN 2B DFS: 5.6% 8.8 yrs class, preoperative basal CT > 30, and age >10 yo Disease free survival

Inclusion criteria: RET mutation carrier with no evidence of disease (including medullary thyroid cancer, pheochromocytoma, or hyperparathyroidism) Primary objective: determine risk of waiting to perform thyroidectomy and central lymph node dissection until stimulated calcitonin levels are elevated. Secondary objective: Identify serum calcitonin level at which metastatic disease is likely to be found Rosella, et al. The Timing of Total Thyroidectomy in RET Gene Mutation Carriers Could Be Personalized and Safely Planned on the Basis of Serum Calcitonin: 18 Years Experience at One Single Center.

84 subjects Group 1 (21) Basal CT: pos Stim CT: pos Basal CT (7) all T1N0 Basal CT >60(13) 24% T1-3 N0 38% N1 Group 2 (31) Basal CT: neg Stim CT: pos 81% T1N0 19% c-cell hplsa Group 3 (32) Basal CT: neg Stim CT: neg 4 tot thyroid all T1 N0 Results

Pediatric-specific results <16 yo (31) 10 MEN2A 18 FMTC 3 MEN2B Elevated basal CT (7) Non MEN2B (4) T1N0 MEN2B (3) N1 or M1 Elevated stimulated CT (8) All T1N0 All disease free at follow up Normal basal and stimulated CT (16) 2-7 year follow up (avg 3.3yr) disease free

Conclusions  RET mutation = lifetime risk of medullary thyroid cancer that is progressive with age.  Degree of serum CT elevation correlates to extent of disease  If CT <60 pg/mL, there were no +nodes  Safe to delay total thyroidectomy in select population until indicated by biochemical markers. Advantages:  Later medicalization of children  Help to further define risk with various RET mutation types to avoid childhood surgery

Benefit to waiting? Cross sectional analysis of Healthcare Cost and Utilization Project National Inpatient Sample (HCUP-NIS) database  1199 children who underwent partial/total thyroidectomy, parathyroidectomy Children ages 0–6: Longer LOS Increased rate of complications Increased rate of recurrent laryngeal nerve-related injuries

Long term follow up data for pediatric thyroidectomy 74 patients between  RLN injury  Incidence of post operative hypoPTH  Medication adherence  Psychological/behavioral problems  Does age of intervention affect rates of the above?

Results 74 patients, ages 3-18, median age 12.5  41% MEN 2A  54% thyroid ca  5% benign disease (goiter) 62% underwent node dissection

 RLN injury  Incidence of post operative hypoPTH  Medication adherence  Psychological/behavioral problems  Does age of intervention affect rates of the above? None 30% with temporary hypoPTH, 8% with permanent hypoPTH 41% with >= 1 episode: refusal from parents, family issues (dual residences), inappropriate administration of meds) 44% with parent-reported psychologic/behavioral problems. Majority related to abnormal thyroid function tests No significant difference with age at operation

References Morris, Lilah, et al. Long-term follow-up data may help manage patient and parent expectations for pediatric patients undergoing thyroidectomy. Surgery. December 2012, 152 (6): Rohmer, V. et al. Prognostic Factors of Disease-Free Survival after Thyroidectomy in 170 Young Patients with a RET Germline Mutation: A Multicenter Study of the Groupe Francais d’Etude des Tumeurs Endocrines. J Clin Endocrinol Metab, March 2011, 96(3):E509 –E518 Rossella Elisei et al The Timing of Total Thyroidectomy in RET Gene Mutation Carriers Could Be Personalized and Safely Planned on the Basis of Serum Calcitonin: 18 Years Experience at One Single Center. J Clin Endocrinol Metab, February 2012, 97(2):426–435 Sosa, JA, Roman, SA. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. Aug 2008; 93(8), 3058=65